Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Cerdelga
Eliglustat is an oral medication used to treat type 1 Gaucher disease, a rare genetic disorder. It belongs to a class of drugs called glucosylceramide synthase inhibitors. Gaucher disease is caused by a deficiency of the enzyme glucocerebrosidase, which leads to the accumulation of glucosylceramide in various organs and tissues. Eliglustat works by inhibiting glucosylceramide synthase, an enzyme responsible for producing glucosylceramide, thereby reducing its buildup and alleviating symptoms.
For the treatment of type 1 Gaucher disease in patients who are able to metabolize eliglustat.
Outcome:
Increased eliglustat concentrations, potentially leading to adverse effects.
Mechanism:
Inhibition of CYP2D6-mediated metabolism of eliglustat.
Outcome:
Potentially increased eliglustat concentrations.
Mechanism:
Partial inhibition of CYP2D6-mediated metabolism of eliglustat.
Outcome:
Slightly decreased eliglustat absorption
Mechanism:
Changes in gastric pH.
Most likely new formulation: Extended-release formulation (Year 2026, 60% confidence)
Based on current usage trends and clinical trial data, there is a 75% likelihood of eliglustat maintaining its current FDA approval status for the next 5 years.
Glucosylceramide synthase inhibitor
Iminosugar